GlassScriptPhysician profile
Latonja Shaw
NPI 1063885515
$11,113.87
in general payments reported to CMS, 2019-2025
53 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,733 · 2022: $3,367 · 2023: $1,784 · 2024: $1,576 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,013.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,356.22 | 2022 | |
| Novo Nordisk INC | $1,181.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,112.33 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $898.55 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $719.34 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $602.26 | 2021-2024 | |
| Amgen INC. | $563.58 | 2021-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $561.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $555.38 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $470.85 | 2021-2025 | |
| Esperion Therapeutics, INC. | $304.29 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $280.89 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $242.95 | 2021-2023 | Xarelto |
| Dexcom, INC. | $233.65 | 2021-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $155.58 | 2024-2025 | Xyosted |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latonja Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.